Kacpura Abigail, Frigeni Marta, Gunther Kathryn, Farach Laura
Department of Pediatrics, Division of Medical Genetics, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA.
Am J Med Genet A. 2022 Jun;188(6):1831-1835. doi: 10.1002/ajmg.a.62687. Epub 2022 Feb 14.
This case report describes a patient with early-onset cobalamin C deficiency who was started on treatment with high-dose parenteral hydroxocobalamin after diagnosis at 13 days of life. Prior to diagnosis, initial presenting symptoms included poor feeding, lethargy, apneic episodes, hypothermia, and hypotonia; these symptoms resolved after initiation of medication. Methylmalonic acid and homocysteine levels were trended and significantly improved with treatment. She was maintained on 2 mg/kg/day dosing of hydroxocobalamin. No adverse effects to treatment were observed. At the time of this report, the patient was 19 months of age; she had not manifested common findings of early-onset cobalamin C deficiency, including microcephaly, poor feeding, growth abnormalities, hypotonia, seizures, maculopathy, or neurodevelopmental delay. This report suggests that early initiation of high-dose hydroxocobalamin is safe and effective.
本病例报告描述了一名早发性钴胺素C缺乏症患者,该患者在出生13天时确诊后开始接受大剂量胃肠外羟钴胺素治疗。在诊断之前,最初的症状包括喂养困难、嗜睡、呼吸暂停发作、体温过低和肌张力减退;用药后这些症状得到缓解。甲基丙二酸和同型半胱氨酸水平呈动态变化,治疗后显著改善。她维持每日2mg/kg的羟钴胺素剂量。未观察到治疗的不良反应。在撰写本报告时,该患者19个月大;她未表现出早发性钴胺素C缺乏症的常见症状,包括小头畸形、喂养困难、生长异常、肌张力减退、癫痫发作、黄斑病变或神经发育迟缓。本报告表明,早期开始大剂量羟钴胺素治疗是安全有效的。